I-BET-762: Selective BET Inhibitor for Inflammation and Cancer Research

Executive Summary: I-BET-762 (B1498, APExBIO) is a highly selective, nanomolar-range BET bromodomain inhibitor that binds the acetyl-lysine binding pocket with high affinity (IC₅₀ 32.5–42.5 nM; Kd 50.5–61.3 nM) (APExBIO). It competitively displaces acetyl-lysine residues, downregulates LPS-inducible genes, and reduces pro-inflammatory cytokine production in vitro and in vivo (Fan et al., 2024). I-BET-762 promotes erastin-induced ferroptosis by targeting ROS and FSP1 pathways in multiple cancer cell lines. The compound is insoluble in water but dissolves in DMSO (≥21.19 mg/mL) and ethanol (≥13.93 mg/mL with sonication). It is recommended for research in epigenetic regulation, inflammation, and cancer biology, particularly where BET protein signaling is implicated (see prior review).

Biological Rationale

The bromodomain and extra-terminal (BET) family proteins act as epigenetic readers, recognizing acetylated lysine motifs on histones to regulate gene transcription (Fan et al., 2024). BET proteins, including BRD2, BRD3, and BRD4, are critical in controlling inflammation and oncogenic transcriptional programs. Aberrant BET activity is linked to increased expression of pro-inflammatory cytokines and oncogenic drivers. Inhibiting BET proteins is a validated approach to modulate pathological gene expression in inflammatory diseases and cancer (see comparative analysis). Ferroptosis, a non-apoptotic, iron-dependent cell death mechanism, is regulated by oxidative stress and is being explored as a therapeutic target in resistant cancers. BET inhibition can sensitize tumor cells to ferroptosis, expanding its utility in cancer biology (mechanism update).

Mechanism of Action of I-BET-762

I-BET-762 binds the acetyl-lysine binding pocket of BET proteins (BRD2/BRD3/BRD4) with nanomolar affinity (IC₅₀: 32.5–42.5 nM; Kd: 50.5–61.3 nM) (APExBIO). The compound competitively displaces acetyl-lysine residues, blocking recruitment of BET proteins to chromatin. This leads to downregulation of LPS-inducible pro-inflammatory genes and chemokines. I-BET-762 exhibits a unique 2:1 binding stoichiometry with BET domains, contributing to its selectivity (see prior review). The inhibitor does not significantly interact with non-BET bromodomain proteins under tested conditions. In cancer models, I-BET-762 increases reactive oxygen species (ROS) and downregulates ferroptosis suppressor protein 1 (FSP1), enhancing erastin-induced ferroptosis in multiple cell lines (Fan et al., 2024).

Evidence & Benchmarks

• I-BET-762 inhibits BET bromodomains with IC₅₀ values of 32.5–42.5 nM (in vitro enzymatic assay, 25°C, pH 7.4) (APExBIO).
• Direct binding affinity (Kd) for BET proteins is 50.5–61.3 nM (biolayer interferometry, 25°C) (APExBIO).
• I-BET-762 treatment reduces LPS-induced cytokine and chemokine gene expression in murine models (in vivo, 10 mg/kg, IP, 24h) (summary article).
• In HEK293T and HeLa cells, I-BET-762 (2 μM, 48h) potentiates erastin-induced ferroptosis, increasing ROS and decreasing FSP1 expression (cell culture, CCK-8 and ChIP assays) (Fan et al., 2024).
• No significant off-target effect on non-BET bromodomain proteins observed in selectivity profiling (panel, 10 μM, 37°C, 1h) (APExBIO).
• I-BET-762 is insoluble in water, but soluble at ≥21.19 mg/mL in DMSO and ≥13.93 mg/mL in ethanol with ultrasonic assistance (solubility test, 25°C) (APExBIO).
• Compound stored at -20°C is stable for months in solid form; solutions should be used promptly to avoid degradation (APExBIO).

Applications, Limits & Misconceptions

I-BET-762 is widely used in research focusing on:

• Epigenetic regulation of transcription in inflammation and cancer.
• Preclinical models of inflammatory disease, including LPS-induced inflammation.
• Cellular models of ferroptosis and oxidative stress response.
• BET protein signaling pathway interrogation in cancer biology.

Its anti-inflammatory effects have been validated in vivo, and it is a benchmark tool for studying BET-mediated gene regulation (see strategic review). Unlike broad-spectrum epigenetic inhibitors, I-BET-762 shows a high degree of selectivity, minimizing off-target chromatin effects. This article extends prior analyses by integrating new data on ferroptosis enhancement and benchmarking solubility/handling protocols (compare with workflow guidance).

Common Pitfalls or Misconceptions

• I-BET-762 is not active against non-BET bromodomain-containing proteins; use is not recommended for broad-spectrum bromodomain inhibition (APExBIO).
• The compound is insoluble in aqueous buffers; improper dissolution can lead to precipitation and loss of activity.
• Prolonged storage in solution at room temperature leads to degradation; always prepare fresh solutions before use (APExBIO).
• Anti-inflammatory efficacy is model-dependent; results in murine models may not fully extrapolate to human systems (Fan et al., 2024).
• Ferroptosis enhancement requires co-treatment with inducers like erastin; I-BET-762 alone does not trigger ferroptosis (Fan et al., 2024).

Workflow Integration & Parameters

For in vitro studies, dissolve I-BET-762 in DMSO (≥21.19 mg/mL) or ethanol with sonication (≥13.93 mg/mL). Avoid aqueous solvents. Recommended working concentrations range from 0.1–2 μM for cell-based assays. For in vivo murine studies, typical dosing is 10 mg/kg intraperitoneally. Store powder at -20°C and use solutions within hours of preparation. I-BET-762 is available from APExBIO as catalog B1498 (I-BET-762 product page). For advanced guidance on assay setup, see I-BET-762: Optimizing BET Inhibition in Cancer Models, which details cell viability and cytotoxicity protocol optimizations for this compound.

Conclusion & Outlook

I-BET-762 is a validated, selective BET bromodomain inhibitor with nanomolar potency, consistent anti-inflammatory effects, and unique capacity to enhance ferroptosis in cancer research models. Its robust selectivity and well-defined handling parameters make it a benchmark tool in epigenetic and transcriptional regulation studies. Current research is expanding its use in combinatorial cancer therapies, especially for FSP1-dependent tumor types (Fan et al., 2024). For reliable sourcing and technical support, APExBIO provides verified quality and documentation for I-BET-762 (APExBIO).